시장보고서
상품코드
1782000

세계의 바이오시밀러 및 생물제제 시장 : 제품 유형별, 용도별, 유통별, 제조 유형별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Biosimilar and Biologics Market, By Product Type, By Application, By Distribution, By Manufacturing Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 269 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

세계의 바이오시밀러 및 생물제제 시장 규모는 2024년 5,563억 944만 달러로, 2025-2032년까지 CAGR 7.81%로 확대될 것으로 예측

바이오시밀러 및 생물제제 시장 - 시장 역학

대히트 생물제제의 특허 만료

바이오시밀러 시장의 가장 큰 성장 촉진요인 중 하나는 대형 생물제제의 특허 만료입니다. 이러한 생물학적 제제는 종종 "블록버스터"라고 불리며 연간 수십억 매출을 창출합니다. 특허가 끝나면, 바이오시밀러 의약품 제조업체가 보다 저렴한 대체품을 개발 및 판매하는 길이 열립니다. 예를 들어, 류마티스 관절염과 크론병의 치료로서 세계에서 가장 많이 팔리는 생물제제 중 하나인 아달리무맙(Humira)은 바이오시밀러가 시장에 진입하기 전에는 연간 200억 달러 이상의 매출을 올렸습니다. 블록버스터 생물제제의 특허 만료은 바이오시밀러 시장 성장의 기본적인 원동력입니다. 경쟁을 가능하게 하고 약가를 낮추고 생물학적 제제에 대한 접근성을 확대함으로써 궁극적으로 보다 지속 가능한 세계의 건강 관리 시스템을 구축할 것입니다. 이 추세는 향후 10년간 더 많은 생물학적 제제가 독점권을 잃고 바이오시밀러 개발과 채용이 급증하는 길을 열어 갈 것입니다.

바이오시밀러 및 생물제제 시장 - 주요 인사이트

우리 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2025-2032년)에 약 7.81%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

제품 유형별로는 생물제제가 2024년 최대 시장 점유율을 나타낼 것으로 예측됐습니다.

용도별로는 암 영역이 2024년에는 주요 용도가 되었습니다.

유통 부문별로는 병원 약국이 2024년에 주요 부문이었습니다.

지역별로는 북미가 2024년 매출을 이끌었습니다.

바이오시밀러 및 생물제제 시장 - 세분화 분석

바이오시밀러 및 생물제제 시장은 제품 유형, 용도, 유통, 제조 유형, 지역에 따라 구분됩니다.

시장은 제품 유형에 따라 생물제제와 바이오시밀러의 두 가지로 분류됩니다. 생물제제는 자가면역질환과 같은 질병을 치료하는 데 사용되는 유기체로 만든 독창적이고 복잡한 의약품입니다. 바이오시밀러는 승인된 생물제제의 고도와 유사한 염가판으로 선발품의 특허가 끊어진 후 개발되어 동등한 안전성과 효능을 기재하고 있습니다.

바이오시밀러 시장은 용도에 따라 두 가지 범주로 나뉩니다. 암, 감염, 자가면역 질환(류마티스 관절염, 건선 등), 혈액 질환(빈혈, 혈우병 등), 당뇨병, 성장 호르몬 결핍증, 안과 질환(황반변성 등), 기타(희귀질환, 불임 치료 등). 암은 세계적으로 주요 사인 중 하나이며, 고령화, 라이프 스타일의 변화, 진단법의 개선에 의해 이환율이 상승하고 있습니다. 생물제제, 특히 단일클론항체와 표적요법은 기존 화학요법에 비해 부작용이 적고, 개별화된 효과적인 해결책을 제공함으로써 암 치료에 혁명을 가져왔습니다. 또한 생물제제와 바이오시밀러의 연구개발투자, 임상검사, 규제당국의 승인에 있어 종양학이 큰 비율을 차지하고 있어 그 우위성을 강화하고 있습니다. 암 환자 증가가 예측되고 정밀의료에 대한 주목이 높아지는 가운데 암 영역은 앞으로도 이 시장에서 가장 수요가 높고 수익성이 높은 용도 부문으로 계속 될 것으로 예측됩니다.

바이오시밀러 및 생물제제 시장 - 지리적 통찰

바이오시밀러와 생물제제 시장은 지리적 지역에 따라 성장 패턴이 다릅니다. 북미, 특히 미국은 첨단 건강 관리 인프라, 강력한 R&D 투자 및 주요 제약 회사의 존재로 인해 생물제제 시장에서 큰 점유율을 차지합니다. 미국에서는 당초 규제나 시장 장벽으로 인해 바이오시밀러 의약품의 도입이 늦었지만, Humira와 같은 블록버스터 의약품의 특허 만료에 따라 도입이 가속되고 있습니다. 유럽은 바이오시밀러에게 가장 성숙하고 확립된 시장으로, 비용 억제 시책, 유럽의 의약품청(EMA)에 의한 지원적인 규제 틀, 의사와 환자의 높은 수용성이 그 원동력이 되고 있습니다. 아시아태평양은 가장 빠르게 성장하는 지역으로 인도, 중국, 한국 등의 국가들이 주요 바이오시밀러 제조업체로 부상하고 있습니다. 이 성장을 뒷받침하는 것은 환자 수가 많고 건강 관리에 대한 액세스가 증가하고 규제가 개선되는 것입니다. 라틴아메리카에서는 각국이 의료 제도를 현대화하고 공공 지출을 줄이기 위해 바이오시밀러를 사용하도록 장려하기 때문에 시장은 순조롭게 확대되고 있습니다. 마지막으로 중동 및 아프리카는 접근과 인프라 정비의 과제는 남아 있지만, 저렴한 생물제제 치료에 대한 수요가 높아지고 있는 신흥 시장입니다. 전반적으로, 바이오시밀러 의약품의 도입은 유럽이 선도하고 있지만, 북미와 아시아태평양이 향후 시장 성장을 견인하게 될 것으로 예측됩니다.

바이오시밀러 및 생물제제 시장 - 경쟁 구도

바이오시밀러와 생물제제 시장 경쟁 구도는 주요 제약 기업과 신흥 생명 공학 기업의 경쟁 간의 적대 관계를 특징으로 합니다. Amgen, Pfizer, Roche, Novartis(Sandoz), Samsung Bioepis, Biocon, Celltrion, Mylan(Viatris) 등 대기업이 시장을 독점하고 있으며, 강력한 R&D 능력, 광범위한 제조 시설, 세계 유통망을 활용하여 시장 점유율을 유지·확대하고 있습니다. 이러한 기업들은 특허가 끊어지거나 끊어지는 수요가 높은 생물제제의 바이오시밀러 개발에 많은 투자를 하고 있습니다. 경쟁은 가격뿐만 아니라 제품의 품질, 규제 당국의 승인, 특허 전략, 의사와 환자의 신뢰를 구축하기 위한 마케팅 노력 등을 기반으로합니다. 또한 파이프라인 포트폴리오를 강화하고 새로운 시장에 진입하기 위한 전략적 제휴, 공동 연구, M&A도 일반적입니다. 이 상황은 규제 요건과 시장 접근의 지역 차이에 의해 더욱 복잡해지고, 각 회사의 바이오시밀러 제품의 세계 위치에 영향을 미칩니다. 시장이 발전함에 따라, 바이오프로세스 기술과 재단사 치료의 혁신은 이러한 급성장 부문에서 경쟁을 유지하려는 기업에게 매우 중요합니다.

목차

제1장 바이오시밀러 및 생물제제 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 바이오시밀러 및 생물제제의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 미래 동향

제4장 바이오시밀러 및 생물제제 산업의 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 매핑
  • 규제 틀 분석

제5장 바이오시밀러 및 생물제제 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아 및 우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 바이오시밀러 및 생물제제 시장 상황

  • 바이오시밀러 및 생물제제 시장 점유율 분석, 2024년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥 기업의 분석

제7장 바이오시밀러 및 생물제제 시장 - 제품 유형별

  • 개요
    • 제품 유형별 부문 점유율 분석
    • 생물제제
      • 단일클론항체(mAbs)
      • 백신
      • 재조합 호르몬(예 : 인슐린, 인간 성장 호르몬)
      • 치료용 단백질(예 : 에리스로포이에틴, 인터페론)
      • 혈액제품
      • 유전자 치료
      • 세포요법
    • 바이오시밀러
      • 단일클론항체 바이오시밀러
      • 재조합 호르몬 바이오시밀러(예 : 인슐린, 성장 호르몬)
      • 에리스로포이에틴 바이오시밀러
      • 필글라스팀 및 페그필글라스팀의 바이오시밀러
      • 인플릭시맙, 아달리무맙, 트라스투주맙의 바이오시밀러
      • 인터페론 바이오시밀러

제8장 바이오시밀러 및 생물제제 시장 - 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 종양학
    • 감염증
    • 자가면역질환(예 : 류마티스 관절염, 건선)
    • 혈액 질환(예 : 빈혈, 혈우병)
    • 당뇨병
    • 성장 호르몬 결핍증
    • 안질환(예 : 황반변성)
    • 기타(예 : 희소질환, 불임치료)

제9장 바이오시밀러 및 생물제제 시장 - 유통별

  • 개요
    • 유통별 부문 점유율 분석
    • 병원 약국
    • 온라인 약국
    • 소매 약국

제10장 바이오시밀러 및 생물제제 시장 - 제조 유형별

  • 개요
    • 제조 유형별 부문 점유율 분석
    • 사내 제조
    • 계약제조조직(CMO)

제11장 바이오시밀러 및 생물제제 시장 - 지역

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 튀르키예
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 - 바이오시밀러 및 생물제제 산업

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 프로파일
    • Amgen Inc.
    • Novartis AG(Sandoz)
    • Pfizer Inc.
    • Roche Holding AG
    • Samsung Bioepis
    • Biocon Ltd.
    • Mylan NV(Viatris)
    • Celltrion Inc.
    • Fresenius Kabi
    • Boehringer Ingelheim
    • Cipla Limited
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz(a Novartis division)
    • Dr. Reddy's Laboratories
    • Intas Pharmaceuticals Ltd.
    • Zhejiang Hisun Pharmaceutical Co., Ltd.
    • LG Chem Life Sciences
    • Pfizer Inc.
    • Hetero Drugs Limited
    • Oncobiologics, Inc.
    • 기타

제13장 애널리스트의 전방위적 전망

JHS 25.08.11

REPORT HIGHLIGHT

Biosimilar and Biologics Market size was valued at US$ 556,309.44 Million in 2024, expanding at a CAGR of 7.81% from 2025 to 2032.

The biosimilars and biologics market represents one of the fastest-growing sectors in the global pharmaceutical industry. Biologics are large, complex molecules or mixtures of molecules derived from living cells used in the treatment, diagnosis, or prevention of diseases. Examples include monoclonal antibodies, vaccines, and recombinant proteins. Fueled by advances in biotechnology, rising prevalence of chronic diseases, patent expirations of blockbuster biologics, and increasing healthcare costs, the market is witnessing rapid transformation.

Biosimilar and Biologics Market- Market Dynamics

Patent Expiration of Blockbuster Biologics

One of the most significant growth drivers in the biosimilars market is the expiration of patents for major biologic drugs. These biologics, often called "blockbusters", generate billions in annual sales. When their patents expire, it opens the door for biosimilar manufacturers to develop and market more affordable alternatives. For instance, Adalimumab (Humira), one of the world's top-selling biologics used to treat rheumatoid arthritis and Crohn's disease, generated over $20 billion/year in revenue before biosimilars entered the market. The expiration of patents on blockbuster biologics is a fundamental driver of growth in the biosimilar market. It enables competition, reduces drug prices, and expands access to biologic therapies-ultimately creating a more sustainable global healthcare system. This trend will continue over the next decade as more biologics lose exclusivity, paving the way for a surge in biosimilar development and adoption.

Biosimilar and Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.81% over the forecast period (2025-2032)

Based on product type segmentation, Biologics was predicted to show maximum market share in the year 2024

Based on application segmentation, Oncology was the leading application in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Biosimilar and Biologics Market- Segmentation Analysis:

The Global Biosimilar and Biologics Market is segmented on the basis of Product Type, Application, Distribution, Manufacturing Type, and Region.

The market is divided into two categories based on product type: Biologics, and Biosimilars. Biologics and Biosimilars. Biologics are original, complex medicines made from living organisms, used to treat diseases like cancer and autoimmune disorders. Biosimilars are highly similar, lower-cost versions of approved biologics, developed after the original product's patent expires, offering comparable safety and effectiveness.

The market is divided into two categories based on application: Oncology, Infectious Diseases, Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis), Blood Disorders (e.g., anemia, hemophilia), Diabetes, Growth Hormone Deficiency, Ophthalmic Disorders (e.g., macular degeneration) and Others (e.g., rare diseases, fertility treatments). Cancer is one of the leading causes of death globally, with a rising incidence due to aging populations, lifestyle changes, and improved diagnostics. Biologics particularly monoclonal antibodies and targeted therapies-have revolutionized cancer treatment by offering personalized, effective solutions with fewer side effects compared to traditional chemotherapy. Additionally, oncology accounts for a large share of R&D investments, clinical trials, and regulatory approvals in both biologics and biosimilars, reinforcing its dominance. With cancer cases projected to rise and the focus on precision medicine growing, oncology will likely remain the most demanding and profitable application area in this market.

Biosimilar and Biologics Market- Geographical Insights

The biosimilar and biologics market shows varying growth patterns across different geographical regions. North America, particularly the United States, holds a major share in the biologics market due to advanced healthcare infrastructure, strong R&D investments, and the presence of key pharmaceutical players. Although biosimilar adoption was initially slow in the U.S. due to regulatory and market barriers, it is now accelerating following the expiration of patents for blockbuster drugs like Humira. Europe is the most mature and established market for biosimilars, driven by cost-containment policies, supportive regulatory frameworks by the European Medicines Agency (EMA), and high physician and patient acceptance. Asia-Pacific is the fastest-growing region, with countries like India, China, and South Korea emerging as major biosimilar manufacturers. This growth is supported by large patient populations, increasing healthcare access, and improving regulatory pathways. In Latin America, the market is expanding steadily as countries modernize their healthcare systems and encourage biosimilar use to reduce public spending. Lastly, the Middle East and Africa represent emerging markets with growing demand for affordable biologic treatments, although access and infrastructure challenges remain. Overall, while Europe leads in biosimilar adoption, North America and Asia-Pacific are set to drive future market growth.

Biosimilar and Biologics Market- Competitive Landscape:

The competitive landscape of the biosimilars and biologics market is characterized by intense rivalry among a mix of established pharmaceutical giants and emerging biotech companies. Major players like Amgen, Pfizer, Roche, Novartis (Sandoz), Samsung Bioepis, Biocon, Celltrion, and Mylan (Viatris) dominate the market, leveraging strong R&D capabilities, extensive manufacturing facilities, and global distribution networks to maintain and expand their market share. These companies are investing heavily in developing biosimilars for high-demand biologics whose patents have expired or are nearing expiration. Competition is not only based on pricing but also on product quality, regulatory approvals, patent strategies, and marketing efforts to build physician and patient trust. Additionally, strategic partnerships, collaborations, and mergers and acquisitions are common to enhance pipeline portfolios and access new markets. The landscape is further complicated by regional differences in regulatory requirements and market access, which influence how companies position their biosimilar products worldwide. As the market evolves, innovation in bioprocessing technologies and tailored therapies will be crucial for companies aiming to stay competitive in this rapidly growing sector.

Recent Developments:

In March 2025, Fresenius Kabi received U.S. FDA approval for two of their denosumab biosimilars, Conexxence and Bomyntra, which are now approved for the same indications as the original reference drugs, Prolia and Xgeva, respectively. This approval enhances treatment options for patients with osteoporosis and cancer-related bone loss, contributing to the growing acceptance of biosimilars in the U.S. market .

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Bioepis
  • Biocon Ltd.
  • Mylan N.V. (Viatris)
  • Celltrion Inc.
  • Fresenius Kabi
  • Boehringer Ingelheim
  • Cipla Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz (a Novartis division)
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • LG Chem Life Sciences
  • Pfizer Inc.
  • Hetero Drugs Limited
  • Oncobiologics, Inc.
  • Others

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Biologics:

  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Recombinant Hormones (e.g., insulin, human growth hormone)
  • Therapeutic Proteins (e.g., erythropoietin, interferons)
  • Blood Products
  • Gene Therapy
  • Cell Therapy

Biosimilars:

  • Monoclonal Antibodies Biosimilars
  • Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
  • Erythropoietin Biosimilars
  • Filgrastim and Pegfilgrastim Biosimilars
  • Infliximab, Adalimumab, Trastuzumab Biosimilars
  • Interferons Biosimilars

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Infectious Diseases
  • Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
  • Blood Disorders (e.g., anemia, hemophilia)
  • Diabetes
  • Growth Hormone Deficiency
  • Ophthalmic Disorders (e.g., macular degeneration)
  • Others (e.g., rare diseases, fertility treatments)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY MANUFACTURING TYPE- MARKET ANALYSIS, 2019 - 2032

  • In-house Manufacturing
  • Contract Manufacturing Organizations (CMOs)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biosimilar and Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilar and Biologics Market Snippet by Product Type
    • 2.1.2. Biosimilar and Biologics Market Snippet by Application
    • 2.1.3. Biosimilar and Biologics Market Snippet by Distribution
    • 2.1.4. Biosimilar and Biologics Market Snippet by Manufacturing Type
    • 2.1.5. Biosimilar and Biologics Market Snippet by Country
    • 2.1.6. Biosimilar and Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilar and Biologics Key Market Trends

  • 3.1. Biosimilar and Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilar and Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilar and Biologics Market Opportunities
  • 3.4. Biosimilar and Biologics Market Future Trends

4. Biosimilar and Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilar and Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biosimilar and Biologics Market Landscape

  • 6.1. Biosimilar and Biologics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilar and Biologics Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Biologics:
      • 7.1.2.1. Monoclonal Antibodies (mAbs)
      • 7.1.2.2. Vaccines
      • 7.1.2.3. Recombinant Hormones (e.g., insulin, human growth hormone)
      • 7.1.2.4. Therapeutic Proteins (e.g., erythropoietin, interferons)
      • 7.1.2.5. Blood Products
      • 7.1.2.6. Gene Therapy
      • 7.1.2.7. Cell Therapy
    • 7.1.3. Biosimilars:
      • 7.1.3.1. Monoclonal Antibodies Biosimilars
      • 7.1.3.2. Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
      • 7.1.3.3. Erythropoietin Biosimilars
      • 7.1.3.4. Filgrastim and Pegfilgrastim Biosimilars
      • 7.1.3.5. Infliximab, Adalimumab, Trastuzumab Biosimilars
      • 7.1.3.6. Interferons Biosimilars

8. Biosimilar and Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Infectious Diseases
    • 8.1.4. Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
    • 8.1.5. Blood Disorders (e.g., anemia, hemophilia)
    • 8.1.6. Diabetes
    • 8.1.7. Growth Hormone Deficiency
    • 8.1.8. Ophthalmic Disorders (e.g., macular degeneration)
    • 8.1.9. Others (e.g., rare diseases, fertility treatments)

9. Biosimilar and Biologics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Biosimilar and Biologics Market - By Manufacturing Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Manufacturing Type, 2024 & 2032 (%)
    • 10.1.2. In-house Manufacturing
    • 10.1.3. Contract Manufacturing Organizations (CMOs)

11. Biosimilar and Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Biosimilar and Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Biosimilar and Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Biosimilar and Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Biosimilar and Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Biosimilar and Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Biosimilar and Biologics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Novartis AG (Sandoz)
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Roche Holding AG
    • 12.2.5. Samsung Bioepis
    • 12.2.6. Biocon Ltd.
    • 12.2.7. Mylan N.V. (Viatris)
    • 12.2.8. Celltrion Inc.
    • 12.2.9. Fresenius Kabi
    • 12.2.10. Boehringer Ingelheim
    • 12.2.11. Cipla Limited
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Sandoz (a Novartis division)
    • 12.2.14. Dr. Reddy's Laboratories
    • 12.2.15. Intas Pharmaceuticals Ltd.
    • 12.2.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 12.2.17. LG Chem Life Sciences
    • 12.2.18. Pfizer Inc.
    • 12.2.19. Hetero Drugs Limited
    • 12.2.20. Oncobiologics, Inc.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제